Activin RIB

Activin RIB Molekülinformation

Englischer Name	Transforming growth factor beta receptor 1	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	7	Target-Alias	EC 2.7.11，TGF-beta type I receptor，Serine/threonine-protein kinase receptor R4，TGFBR1，Activin A receptor type II-like protein kinase of 53kD，Transforming Growth Factor Beta Receptor 1，Transforming Growth Factor-Beta Receptor Type I，Activin A Receptor Type II-Like Kinase， 53kDa，Activin Receptor-Like Kinase 5，TGFR-1，ALK-5，ALK5，SKR4，Mutant Transforming Growth Factor Beta Receptor I，TGF-Beta Receptor Type-1，TGF-Beta Receptor Type I，EC 2.7.11.30，ACVRLK4，LDS1A，LDS2A，AAT5，LDS1，TBRI，ESS1，MSSE，TbetaR-I，Transforming Growth Factor Beta Receptor I，Multiple Self-Healing Squamous Epithelioma，TBR-I，Receptor， Transforming Growth Factor-beta Type I，EC:2.7.11.30
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	Transforming growth factor beta receptor 1
Target-Alias	EC 2.7.11，TGF-beta type I receptor，Serine/threonine-protein kinase receptor R4，TGFBR1，Activin A receptor type II-like protein kinase of 53kD，Transforming Growth Factor Beta Receptor 1，Transforming Growth Factor-Beta Receptor Type I，Activin A Receptor Type II-Like Kinase， 53kDa，Activin Receptor-Like Kinase 5，TGFR-1，ALK-5，ALK5，SKR4，Mutant Transforming Growth Factor Beta Receptor I，TGF-Beta Receptor Type-1，TGF-Beta Receptor Type I，EC 2.7.11.30，ACVRLK4，LDS1A，LDS2A，AAT5，LDS1，TBRI，ESS1，MSSE，TbetaR-I，Transforming Growth Factor Beta Receptor I，Multiple Self-Healing Squamous Epithelioma，TBR-I，Receptor， Transforming Growth Factor-beta Type I，EC:2.7.11.30
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	7
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Activin RIB Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
ACB-H52H4	Human	HEK293	Human Activin RIB / ACVR1B Protein, His Tag				In den Warenkorb legen

Gesamtmenge1

Activin RIB Molekülhintergrund

Activin receptor type-1B (ACVR1B) is also known as Activin receptor-like kinase 4 (ALK-4), Serine/threonine-protein kinase receptor R2 (SKR2), which belongs to the protein kinase superfamily, TKL Ser/Thr protein kinase family and TGFB receptor subfamily. ACVR1B contains one GS domain and one protein kinase domain. The catalytic activity of ACVR1B is “ATP + [receptor-protein] = ADP + [receptor-protein] phosphate”. ACVR1B acts as a transducer of activin or activin like ligands (e.g., inhibin) signals. Activin binds to either ACVR2A or ACVR2B and then forms a complex with ACVR1B. These go on to recruit the R-SMADs SMAD2 or SMAD3. ACVR1B also transduces signals of nodal, GDF-1, and Vg1.

Activin RIB Molekülalias

ACVR1b,ALK4,ACVRLK4,ACTR-IB,SKR2

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Galunisertib	LY-2157299	Phase 3 Clinical	Eli Lilly And Company	Amyotrophic Lateral Sclerosis; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Metastatic breast cancer; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details
GF-101	GFH-018; GF-101; GFH018	Phase 2 Clinical	Genfleet Therapeutics (Shanghai) Co Ltd	Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Liver Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
Tosposertib phosphate	TU-2218; NCE401; NCE-401	Phase 2 Clinical	TiumBio Co Ltd	Idiopathic Pulmonary Fibrosis; Solid tumours	Details
Ontunisertib	ORG-129; AGMB-129	Phase 2 Clinical	Origo Biopharma Sociedad Litmitada	Crohn Disease	Details
TRK-250	TRK-250; BNC-1021	Phase 1 Clinical	Bonac Corp	Idiopathic Pulmonary Fibrosis	Details
Oxinseti	SH-3051	Phase 1 Clinical	Nanjing Sanhome Pharmaceutical Co Ltd	Liver Neoplasms; Solid tumours	Details
AGMB-447	AGMB-447; ORG-447	Phase 1 Clinical	AgomAb Therapeutics NV	Idiopathic Pulmonary Fibrosis	Details